REGN5459
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for REGN5459, covering 2025-05-30 to 2025-05-30. Get the full timeline:
Most recent: Clinical Trial Update: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) [Phase 1, Phase 2]